Table 1 Baseline demographic and clinical characteristics
Characteristic | N = 39 |
|---|---|
Median age (range) | 53 (40–74) |
Sex | |
Male, n (%) | 36 (92) |
Female, n (%) | 3 (8) |
Race/ethnicity | |
Caucasian, n (%) | 31 (80) |
Black, n (%) | 4 (10) |
Hispanic, n (%) | 4 (10) |
Other, n (%) | 0 |
Median BMI (range) | 25.9 (17.3–36.4) |
Baseline HIV viral load | |
< 50 copies/mL, n (%) | 28 (72) |
50–200 copies/mL, n (%) | 6 (15) |
201–399 copies/mL, n (%) | 2 (5) |
≥ 400 copies/mL, n (%) | 3 (8) |
Median baseline CD4+ cell count, cells/mm3 (range) | 564 (92–1217) |
HIV disease status | |
Asymptomatic, n (%) | 32 (82) |
Symptomatic, n (%) | 7 (18) |
AIDS, n (%) | 0 |
Regimen prior to switching to DCR | |
Dual NRTI + PI | 15 (38) |
Dual NRTI + RAL | 6 (15) |
Dual NRTI + NNRTI | 5 (13) |
TDF/FTCEVG/c | 2 (5) |
DRV/r + RAL | 1 (3) |
Regimens containing ≥ 3 ARV classes | 10 (26) |
Prior ARV experience | |
> 2 NRTIs, n (%) | 25 (64) |
1 INSTI, n (%) | 22 (56) |
> 1 INSTI, n (%) | 2 (5) |
Median number of ARV regimens prior to DCR (range) | 4 (1–11) |
Baseline DCR | |
DTG + ABC/3TC | 18 (46) |
DTG + TDF/FTC | 14 (36) |
DTG + DRV/r | 2 (5) |
DTG + TDF/FTC/RPV + DRV/r | 2 (5) |
DTG + RPV | 1 (3) |
DTG/ABC/3TC + TDF | 1 (3) |
DTG + TDF/FTC + RPV | 1 (3) |
Active ARV drugs in DCR based on historical genotypes | |
DTG functional monotherapy, n (%) | 19 (49) |
DTG + non-cytosine nucleoside analog, n (%) | 20 (51) |
DTG + TDF, n (%) | 9 (23) |
DTG + ABC, n (%) | 11 (28) |
Historical genotypic resistance | |
Overall group, n | 39 |
Pattern of NRTI RAMs | |
M184V/I alone, n (%) | 16 (41) |
M184V/I + 1 NRTI RAM, n (%) | 5 (13) |
M184V/I + > 1 NRTI RAM, n (%) | 18 (46) |
Number of RAMS | |
NRTI RAMs, median (range) | 2 (0–9) |
NNRTI RAMs, median (range) | 2 (0–6) |
PI RAMs, median (range) | 4 (0–14) |
INSTI RAMs, median (range) | 0 (0–1) |
DTG functional monotherapy, n (%) | 19 (49) |
NRTI RAMs, median (range) | 5 (2–9) |
INSTI RAMs, median (range) | 0 (0–1) |
DTG + non-cytosine nucleoside analog, n (%) | 20 (51) |
NRTI RAMs, median (range) | 1 (0–8) |
INSTI RAMs, median (range) | 0 (0–1) |
Predicted ARV drug resistance based on historical genotype | |
TDF resistance, n (%) | 12 (31) |
ABC resistance, n (%) | 21 (54) |
3TC or FTC resistance, n (%) | 39 (100) |
RPV resistance, n (%) | 4 (10) |
DRV resistance, n (%) | 4(10) |